Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 125

1.

Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.

Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.

Clin Neuropharmacol. 2018 Sep/Oct;41(5):171-176. doi: 10.1097/WNF.0000000000000294.

PMID:
30024443
2.
3.
4.

Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.

Lus G, Cantello R, Danni MC, Rini A, Sarchielli P, Tassinari T, Signoriello E.

Neurodegener Dis Manag. 2018 Apr;8(2):105-113. doi: 10.2217/nmt-2017-0056. Epub 2018 Apr 23.

PMID:
29683408
5.

Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model.

Callejas GH, Figueira RL, Gonçalves FLL, Volpe FAP, Zuardi AW, Crippa JA, Hallak JE, Sbragia L.

Braz J Med Biol Res. 2018 Mar 15;51(5):e7132. doi: 10.1590/1414-431X20177132.

6.

The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.

Russo M, Dattola V, Logiudice AL, Ciurleo R, Sessa E, De Luca R, Bramanti P, Bramanti A, Naro A, Calabrò RS.

Medicine (Baltimore). 2017 Nov;96(46):e8826. doi: 10.1097/MD.0000000000008826.

7.

What's new in multiple sclerosis spasticity research? Poster session highlights.

Linker R.

Neurodegener Dis Manag. 2017 Nov;7(6s):51-53. doi: 10.2217/nmt-2017-0043.

PMID:
29143588
8.

Multiple sclerosis symptoms and spasticity management: new data.

Izquierdo G.

Neurodegener Dis Manag. 2017 Nov;7(6s):7-11. doi: 10.2217/nmt-2017-0034. Review.

PMID:
29143581
9.
10.

Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.

Giacoppo S, Bramanti P, Mazzon E.

Mult Scler Relat Disord. 2017 Oct;17:22-31. doi: 10.1016/j.msard.2017.06.015. Epub 2017 Jun 27. Review.

PMID:
29055461
11.

Is cannabis an effective treatment for joint pain?

Miller RJ, Miller RE.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):59-67. Epub 2017 Sep 28. Review.

12.

[Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience].

Grao-Castellote C, Torralba-Collados F, Gonzalez LM, Giner-Pascual M.

Rev Neurol. 2017 Oct 1;65(7):295-302. Spanish.

13.

Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.

Philpott HT, OʼBrien M, McDougall JJ.

Pain. 2017 Dec;158(12):2442-2451. doi: 10.1097/j.pain.0000000000001052.

14.

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.

Marinelli L, Balestrino M, Mori L, Puce L, Rosa GM, Giorello L, Currà A, Fattapposta F, Serrati C, Gandolfo C, Abbruzzese G, Trompetto C.

BMJ Open. 2017 Sep 7;7(9):e016843. doi: 10.1136/bmjopen-2017-016843.

15.

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, Gasperini C, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group.

PLoS One. 2017 Aug 1;12(8):e0180651. doi: 10.1371/journal.pone.0180651. eCollection 2017.

16.

Cannabidiol administration reduces sublesional cancellous bone loss in rats with severe spinal cord injury.

Li D, Lin Z, Meng Q, Wang K, Wu J, Yan H.

Eur J Pharmacol. 2017 Aug 15;809:13-19. doi: 10.1016/j.ejphar.2017.05.011. Epub 2017 May 4.

PMID:
28479140
17.

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.

Keating GM.

Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6. Review.

PMID:
28293911
18.

What is new in multiple sclerosis spasticity research? Poster session highlights.

Ghezzi A.

Neurodegener Dis Manag. 2016 Dec;6(6s):45-47.

PMID:
27874498
19.

Country breakout session highlights.

Ghezzi A, Filli L, Solaro C, Mekies C, Landete L, Lycke J.

Neurodegener Dis Manag. 2016 Dec;6(6s):41-44.

PMID:
27874497
20.

Evolution of multiple sclerosis spasticity-associated symptoms: latest data.

Flachenecker P.

Neurodegener Dis Manag. 2016 Dec;6(6s):9-12. Review.

PMID:
27874495

Supplemental Content

Loading ...
Support Center